Modality
Nanobody
MOA
DLL3 ADC
Target
EGFR
Pathway
Checkpoint
Wilms
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Jun 2029
Phase 2Current
NCT06593156
1,998 pts·Wilms
2018-12→2029-06·Completed
1,998 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-174mo agoBTD· Wilms
2029-06-103.2y awayPh2 Data· Wilms
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2
Complet…
Catalysts
BTD
2025-11-17 · 4mo ago
Wilms
Ph2 Data
2029-06-10 · 3.2y away
Wilms
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06593156 | Phase 2 | Wilms | Completed | 1998 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| Adagraderotide | Olema | Phase 2 | EGFR |